FIPB recommends Cadila Healthcare’s proposal for equity infusion to Cabinet panel

26 Aug 2015 Evaluate

Foreign Investment Promotion Board (FIPB) has recommended Cadila Healthcare’s proposal for equity infusion of Rs 5000 crore to the Cabinet Committee on Economic Affairs (CCEA). The company is seeking approval for fresh equity infusion of up to Rs 5,000 crore under FDI route by QIBs through Qualified Institutional Placement on a private placement basis for the expansion of the business. Currently, the Finance Ministry can approve investments up to Rs 3,000 crore with amounts exceeding that having to be referred to the Cabinet panel.

Zydus Cadila is an innovative, global pharmaceutical company that discovers, develops, manufactures and markets a broad range of healthcare therapies. It is the only Indian pharma company to launch its own patented NCE - Lipaglyn, the world’s first drug to be approved for the treatment of diabetic dyslipidemia.

Zydus Lifesciences Share Price

876.10 3.15 (0.36%)
21-Jan-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1612.55
Dr. Reddys Lab 1155.50
Cipla 1369.55
Zydus Lifesciences 876.10
Lupin 2139.40
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×